Analysts Set Gyre Therapeutics, Inc. (NASDAQ:GYRE) Price Target at $17.00

Shares of Gyre Therapeutics, Inc. (NASDAQ:GYRE) have been assigned an average rating of “Hold” from the five analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and three have given a buy recommendation to the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $17.00.

GYRE has been the subject of a number of research reports. Zacks Research raised shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Friday, November 14th. Wall Street Zen upgraded shares of Gyre Therapeutics from a “hold” rating to a “buy” rating in a research report on Saturday, November 15th. Finally, Weiss Ratings reissued a “sell (d)” rating on shares of Gyre Therapeutics in a research note on Thursday, January 22nd.

Institutional Trading of Gyre Therapeutics

Hedge funds have recently bought and sold shares of the company. State of Alaska Department of Revenue bought a new position in Gyre Therapeutics during the third quarter valued at approximately $38,000. Bank of America Corp DE boosted its stake in shares of Gyre Therapeutics by 28.8% in the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after purchasing an additional 1,402 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Gyre Therapeutics by 84.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock valued at $47,000 after purchasing an additional 2,961 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in Gyre Therapeutics by 77.8% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after purchasing an additional 3,244 shares during the period. Finally, Dimensional Fund Advisors LP bought a new stake in Gyre Therapeutics in the fourth quarter worth $77,000. Institutional investors own 23.99% of the company’s stock.

Gyre Therapeutics Trading Down 3.3%

Shares of GYRE opened at $8.24 on Monday. Gyre Therapeutics has a 12-month low of $6.11 and a 12-month high of $13.75. The company has a market cap of $793.78 million, a PE ratio of 274.76 and a beta of 1.97. The stock has a 50-day moving average price of $7.78 and a 200-day moving average price of $7.77.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.